Bioactive coronary stent coating based on layer-by-layer technology for siRNA release

Hossfeld, Susanne; Nolte, Andrea; Hartmann, Hanna; Recke, M.; Schaller, Martin; Walker, Tobias; Kjems, Jørgen; Schlosshauer, Bürkhard; Stoll, Dieter; Wendel, Hans Peter; Krastev, Rumen

doi:10.1016/j.actbio.2013.01.013

Cited by 58 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A proof of concept study demonstrated that LbL coated siRNA on cardiovascular stents withstood ethylene oxide sterilization and could deliver siRNA nanoparticles to porcine arteries ex vivo . 118 Simple adjustments to the current equipment would enable LbL coating with greater control over release kinetics, allow for changes in dosage, and include biomolecules that were previously difficult to deposit.…”

Section: Current Challenges and Future Directionsmentioning

confidence: 99%

Nanocoating for biomolecule delivery using layer-by-layer self-assembly

et al. 2015

View full text Add to dashboard Cite

Since its introduction in the early 1990s, layer-by-layer (LbL) self-assembly of films has been widely used in the fields of nanoelectronics, optics, sensors, surface coatings, and controlled drug delivery. The growth of this industry is propelled by the ease of film manufacture, low cost, mild assembly conditions, precise control of coating thickness, and versatility of coating materials. Despite the wealth of research on LbL for biomolecule delivery, clinical translation has been limited and slow. This review provides an overview of methods and mechanisms of loading biomolecules within LbL films and achieving controlled release. In particular, this review highlights recent advances in the development of LbL coatings for the delivery of different types of biomolecules including proteins, polypeptides, DNA, particles and viruses. To address the need for co-delivery of multiple types of biomolecules at different timing, we also review recent advances in incorporating compartmentalization into LbL assembly. Existing obstacles to clinical translation of LbL technologies and enabling technologies for future directions are also discussed.

show abstract

Section: Current Challenges and Future Directionsmentioning

confidence: 99%

Nanocoating for biomolecule delivery using layer-by-layer self-assembly

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Mechanisms to modulate release could lead to a more therapeutically beneficial delivery system that can be integrated with stent implants. Other work has revealed the feasibility of layer-by-layer coating of stents as an siRNA therapeutic delivery system, although gene silencing efficacy from the coated stents was not established 136 . Gene therapy is a potentially transformative way to address the high-impact area of vascular graft patency, and further development of these and other local delivery systems will aid in identifying a translatable system.…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

Technologies for controlled, local delivery of siRNA

Sarett

Nelson

Duvall

2015

Journal of Controlled Release

View full text Add to dashboard Cite

The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRNA translation is local therapies, as delivering siRNA directly to its site of action helps to ensure that a sufficient dose reaches the target tissue, lessens the potential for off-target side effects, and circumvents the substantial systemic delivery barriers. While topical siRNA delivery has progressed into numerous clinical trials, an enormous opportunity also exists to develop sustained-release, local delivery systems that enable both spatial and temporal control of gene silencing. This review focuses on material platforms that establish both localized and controlled gene silencing, with emphasis on the systems that show most promise for clinical translation.

show abstract

“…The coated stents were tested in an ex vivo model with carotid porcine arteries and provoked the uptake of siRNA/chitosan NPs into the artery walls. The good hemocompatibility of the multilayers and the possibility of sterilizing the bioactive stents with ETO make this system a potential candidate for combating coronary diseases [161]. Recently, San Juan et al .…”

Section: Local Delivery Of Sirna For Atherosclerosis and Restenosimentioning

confidence: 99%

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

et al. 2013

View full text Add to dashboard Cite

Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future.

show abstract

Bioactive coronary stent coating based on layer-by-layer technology for siRNA release

Cited by 58 publications

References 34 publications

Nanocoating for biomolecule delivery using layer-by-layer self-assembly

Nanocoating for biomolecule delivery using layer-by-layer self-assembly

Technologies for controlled, local delivery of siRNA

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

Contact Info

Product

Resources

About